Abbott Ireland released plans to invest €85 million at its pharmaceutical manufacturing operation in Sligo, Ireland. This investment will result in the creation of up to approximately 175 highly skilled jobs, these new roles will include engineering, quality, pharmaceutical science and other science-based areas.
The majority of the jobs will be added during the construction phase and the remainder will come on stream post the completion of the expansion. In addition, construction employment will create up to 150 temporary jobs. The expansion of the facility will be completed in 2014. The investment is supported by the Irish Government through IDA Ireland.
Dr. Azita Saleki-Gerhardt, President, Global Pharmaceutical Operations, Abbott said “Abbott has had a presence in Ireland for more than 65 years and began manufacturing in the country in 1974. Sligo is an important part of Abbott’s pharmaceutical manufacturing network and we are pleased to expand it to support future production needs. The success of our Sligo facility is due to the dedication of its staff and management. This state-of-the-art expansion will enable us to produce innovative therapies that we expect will represent significant advances in the treatment of cancer, chronic kidney disease and viral infections,”